COST OF BEST SUPPORTIVE CARE IN THE TREATMENT OF MODERATE-TO-SEVERE PSORIATIC ARTHRITIS IN THE UNITED STATES

被引：0
|
作者：
Tencer, T. [1 ]
Li, S. [2 ]
Zhang, F. [1 ]
机构：
[1] Celgene Corp, Summit, NJ USA
[2] Celgene Corp, Warren, NJ USA
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.1129
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A222 / A222
页数：1
相关论文
共 50 条
  • [41] Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK
    Schweikert, Bernd
    Malmberg, Chiara
    Akerborg, Orjan
    Kumar, Gayathri
    Nott, Debby
    Kiri, Sandeep
    Sapin, Christophe
    Hartz, Susanne
    PHARMACOECONOMICS-OPEN, 2020, 4 (04) : 635 - 648
  • [42] Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
    Schlueter, Max
    Finn, Elaine
    Diaz, Silvia
    Dilla, Tatiana
    Inciarte-Mundo, Jose
    Fakhouri, Walid
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2019, 11 : 395 - 403
  • [43] Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan
    Chen, Der-Yuan
    Hsu, Ping-Ning
    Tang, Chao-Hsiun
    Claxton, Lindsay
    Valluri, Satish
    Gerber, Robert A.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (08) : 777 - 787
  • [44] Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-to-Severe Psoriasis in the United States
    Steven R. Feldman
    Shipra Rastogi
    Jay Lin
    Dermatology and Therapy, 2018, 8 : 441 - 453
  • [45] Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-to-Severe Psoriasis in the United States
    Feldman, Steven R.
    Rastogi, Shipra
    Lin, Jay
    DERMATOLOGY AND THERAPY, 2018, 8 (03) : 441 - 453
  • [46] Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China
    Tian, Lei
    Xiong, Xiaomo
    Guo, Qiang
    Chen, Yixi
    Wang, Luying
    Dong, Peng
    Ma, Aixia
    PHARMACOECONOMICS, 2020, 38 (12) : 1345 - 1358
  • [47] Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China
    Lei Tian
    Xiaomo Xiong
    Qiang Guo
    Yixi Chen
    Luying Wang
    Peng Dong
    Aixia Ma
    PharmacoEconomics, 2020, 38 : 1345 - 1358
  • [48] Economic Impact of Above-Label Dosing with Biologics in Patients with Moderate-to-Severe Psoriatic Arthritis
    Schwartzman, Sergio
    Li, Yunfeng
    Zhou, Huanxue
    Herrera, Vivian
    Palmer, Jacqueline B.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [49] Multidisciplinary dermatology–rheumatology management for patients with moderate-to-severe psoriasis and psoriatic arthritis: a systematic review
    Tatiana Cobo-Ibáñez
    Virginia Villaverde
    Daniel Seoane-Mato
    Santiago Muñoz-Fernández
    Mercedes Guerra
    Petra Díaz del Campo
    Juan D. Cañete
    Rheumatology International, 2016, 36 : 221 - 229
  • [50] Effect of Psoriatic Arthritis on Treatment Response in Patients With Moderate to Severe Psoriasis
    Greb, Jacqueline E.
    Garber, Caren
    Gottlieb, Alice B.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2016, 15 (08) : 917 - 922
12345